| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 公司作为中国康复医疗器械行业内的研发引领型企业，为全国各级医疗机构、养老机构、残疾人康复中心、福利院、教育系统等机构以及家庭提供系列康复产品及整体解决方案。 公司始终以技术创新为公司发展的第一驱动力，秉承“坚持科技创新支撑，产学研用一体，引领康复未来”的发展理念，致力于疼痛康复、神经康复、骨科康复、产后康复、医养结合等领域智能康复设备的自主研发、生产与销售，协助各地打造覆盖全人群、全生命周期的智慧康养服务保障体系。 公司深耕康复医疗器械领域18年，截至本招股意向书签署日，已取得139项医疗器械注册及备案产品。公司经过长期的沉淀与发展，形成了20大系列、400多种自有产品的丰富产品结构。在公司产品中，颈腰椎治疗多功能牵引床、极超短波治疗机、经颅磁脑病生理治疗仪等38种产品被列入国家中医药管理局中医诊疗设备评估选型推荐品目；体外冲击波治疗仪、四肢联动康复训练仪、认知障碍康复评估训练系统等8种产品入选国家卫健委委托中国医学装备协会遴选的优秀国产医疗设备目录。同时，公司被列入中央军委后勤保障部釆购目录，并被评为一级生产型供应商。公司在冲击波、光疗、电疗、磁疗等30余个技术领域拥有自主知识产权保护下的核心技术，目前已获授权发明专利17项、实用新型专利410余项、软件著作权60余项。公司及其子公司多次参与国家及省级重点研发计划，其中国家重点研发计划包括国家科技部组织的2017年度“智能机器人”重点专项中的“生-机智能交互与生机电一体化机器人技术”项目、2019年度“智能机器人”重点专项中的“脊髓损伤康复机器人研制与应用示范”项目等，省级重点研发计划包括省工信厅、省财政厅联合组织的2019年河南省工业互联网平台培育项目中的“康复医疗设备工业互联网云平台”项目等。公司参与起草或参与评定康复医疗器械领域的国家或行业标准达27项，包括国家质量监督检验检疫总局及国家标准化管理委员会联合发布的国家标准《下肢康复训练设备的分类及通用技术条件（征求意见稿）》以及国家药品监督管理局发布的《经络刺激仪》、《电动上下肢圆周运动训练设备》等行业标准。并且，公司自主研发产品中，有32项获得省级科技成果认证，包括智能关节康复器、四肢联动康复训练仪等。 公司是目前国内少数具有全系列康复医疗器械研发、生产能力的企业之一。公司主营产品以各级医疗机构需配置的康复医疗器械产品为主，公司主要产品可涵盖声疗、光疗、电疗、磁疗、物理治疗（PT）、作业治疗（OT）及康复评定产品等，已经覆盖康复评定、训练、理疗等康复医疗器械主要领域。 | ||||||||||||||||||||||||
| Main Business | 康复医疗器械研发、生产、销售和服务。 | ||||||||||||||||||||||||
| Legal Representative | 何永正 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 郭军玲 | ||||||||||||||||||||||||
| Solicitors | 上海市通力律师事务所 | ||||||||||||||||||||||||
| Auditors | 立信会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0372-7776088 | ||||||||||||||||||||||||
| Fax No | 0372-7776066 | ||||||||||||||||||||||||
| Website | www.xyyl.com | ||||||||||||||||||||||||
| xymedical@xyyl.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 31/03/2021 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 1.440 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.530 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 13.068 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 5.426B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |